CytomX Therapeutics (CTMX) Retained Earnings (2014 - 2026)
CytomX Therapeutics' (CTMX) quarterly Retained Earnings came in at $1.1 billion in Q1 2026, up 51.5% YoY from $693.1 million in Q1 2025, and up 945879.28% on a QoQ basis from $111000.0 in Q4 2025.
CytomX Therapeutics (CTMX) Retained Earnings (2014 - 2026) Analysis & Trends
CytomX Therapeutics (CTMX) has 13 years of Retained Earnings data on file, last reported at $1.1 billion in Q1 2026.
- Quarterly Retained Earnings rose 51.5% year-over-year to $1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 51.5% YoY) and the FY2025 annual result came in at $111000.0, up 311.11% from the prior year.
- Retained Earnings rose to $1.1 billion in Q1 2026, from $111000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $1.1 billion in Q1 2026 to a low of -$727.3 million in Q2 2023.
- A 5-year average of -$150.1 million and a median of -$63000.0 in 2023 frame the typical range for Retained Earnings.
- Annual changes were most pronounced in 2022 — Retained Earnings soared 263371.49% — and 2025, when it tumbled 16705100.0%.
- Tracing CTMX's Retained Earnings over 5 years: stood at $637.1 million in 2022, then tumbled by 213.55% to -$723.4 million in 2023, then surged by 100.0% to $27000.0 in 2024, then jumped by 311.11% to $111000.0 in 2025, then soared by 945879.28% to $1.1 billion in 2026.
- The last three Retained Earnings figures came in at $1.1 billion (Q1 2026), $111000.0 (Q4 2025), and $104000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -4.00 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.05 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -104.13 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 4.38 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -6.33 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 6.57 Bn |
| 10 | CytomX Therapeutics | 732.14 Mn | 401.86 Mn | - | 1.05 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.05 Bn |
| Mar 31, 2026 | 1.05 Bn |
| Dec 31, 2025 | 111,000.00 |
| Sep 30, 2025 | 104,000.00 |
| Jun 30, 2025 | -668.21 Mn |
| Mar 31, 2025 | 693.10 Mn |
| Dec 31, 2024 | 27,000.00 |
| Sep 30, 2024 | -710.46 Mn |
| Jun 30, 2024 | -4,000.00 |
| Mar 31, 2024 | 677.99 Mn |
| Dec 31, 2023 | -723.45 Mn |
| Sep 30, 2023 | -63,000.00 |
| Jun 30, 2023 | -727.28 Mn |
| Mar 31, 2023 | -726.19 Mn |
| Dec 31, 2022 | 637.12 Mn |
| Sep 30, 2022 | -714.10 Mn |
| Jun 30, 2022 | -685.04 Mn |
| Mar 31, 2022 | -655.54 Mn |
| Dec 31, 2021 | -242,000.00 |
| Sep 30, 2021 | -588.74 Mn |